Voldborg B R, Damstrup L, Spang-Thomsen M, Poulsen H S
Section for Radiation Biology, Finsen Centre, Rigshospitalet, Copenhagen, Denmark.
Ann Oncol. 1997 Dec;8(12):1197-206. doi: 10.1023/a:1008209720526.
The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface, where the binding of a ligand activates a tyrosine kinase in the intracellular region of the receptor. This tyrosine kinase phosphorylates a number of intracellular substrates that activates pathways leading to cell growth, DNA synthesis and the expression of oncogenes such as fos and jun. EGFR is thought to be involved the development of cancer, as the EGFR gene is often amplified, and/or mutated in cancer cells. In this review we will focus on: (I) the structure and function of EGFR, (II) implications of receptor/ligand coexpression and EGFR mutations or overexpression, (III) its effect on cancer cells, (IV) the development of the malignant phenotype and (V) the clinical aspects of therapeutic targeting of EGFR.
表皮生长因子受体(EGFR)是一种生长因子受体,当其通过与一种配体结合而被激活时,可诱导细胞分化和增殖。该受体位于细胞表面,配体的结合会激活受体胞内区域的酪氨酸激酶。这种酪氨酸激酶会使多种细胞内底物磷酸化,从而激活导致细胞生长、DNA合成以及癌基因(如fos和jun)表达的信号通路。由于EGFR基因在癌细胞中常发生扩增和/或突变,因此认为EGFR与癌症的发生发展有关。在本综述中,我们将重点关注:(I)EGFR的结构和功能;(II)受体/配体共表达以及EGFR突变或过表达的影响;(III)其对癌细胞的作用;(IV)恶性表型的发展;(V)EGFR治疗靶点的临床方面。